MediciNova, Inc. (MNOV): Price and Financial Metrics


MediciNova, Inc. (MNOV): $2.29

0.10 (+4.57%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MNOV to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MNOV Stock Summary

  • The ratio of debt to operating expenses for MEDICINOVA INC is higher than it is for about merely 6.04% of US stocks.
  • MNOV's price/sales ratio is 2,772.75; that's higher than the P/S ratio of 99.78% of US stocks.
  • As for revenue growth, note that MNOV's revenue has grown -99.06% over the past 12 months; that beats the revenue growth of only 0.66% of US companies in our set.
  • Stocks that are quantitatively similar to MNOV, based on their financial statements, market capitalization, and price volatility, are NVEC, AEZS, GNFT, VCNX, and IKT.
  • MNOV's SEC filings can be seen here. And to visit MEDICINOVA INC's official web site, go to medicinova.com.

MNOV Valuation Summary

  • In comparison to the median Healthcare stock, MNOV's price/sales ratio is 57019.59% higher, now standing at 2770.3.
  • MNOV's price/sales ratio has moved up 2655.1 over the prior 194 months.

Below are key valuation metrics over time for MNOV.

Stock Date P/S P/B P/E EV/EBIT
MNOV 2022-11-01 2770.3 1.3 -7.8 -2.9
MNOV 2022-10-31 2705.4 1.3 -7.7 -2.7
MNOV 2022-10-28 2824.3 1.4 -8.0 -3.0
MNOV 2022-10-27 2716.2 1.3 -7.7 -2.7
MNOV 2022-10-26 2783.8 1.3 -7.9 -2.9
MNOV 2022-10-25 2724.3 1.3 -7.7 -2.7

MNOV Growth Metrics

    Its 2 year cash and equivalents growth rate is now at 10.38%.
  • Its 4 year price growth rate is now at -15.01%.
  • Its 5 year cash and equivalents growth rate is now at 154.29%.
Over the past 33 months, MNOV's revenue has gone up $37,500.

The table below shows MNOV's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 0.0375 -12.83896 -13.07773
2022-03-31 0.0375 -9.256053 -13.33287
2021-12-31 4.0375 -9.381605 -10.13425
2021-09-30 4.0375 -7.691724 -11.0364
2021-06-30 4 -8.584199 -11.16105
2021-03-31 4 -11.80169 -11.32814

MNOV's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MNOV has a Quality Grade of D, ranking ahead of 17.27% of graded US stocks.
  • MNOV's asset turnover comes in at 0.047 -- ranking 325th of 680 Pharmaceutical Products stocks.
  • ACER, SCYX, and ATNM are the stocks whose asset turnover ratios are most correlated with MNOV.

The table below shows MNOV's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.047 1 -2.232
2021-03-31 0.049 1 -2.359
2020-12-31 0.000 NA -3.663
2020-09-30 0.000 NA -3.396
2020-06-30 0.000 NA -3.088
2020-03-31 0.000 NA -2.751

MNOV Price Target

For more insight on analysts targets of MNOV, see our MNOV price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $16.50 Average Broker Recommendation 1.33 (Strong Buy)

MNOV Stock Price Chart Interactive Chart >

Price chart for MNOV

MNOV Price/Volume Stats

Current price $2.29 52-week high $3.59
Prev. close $2.19 52-week low $1.96
Day low $2.21 Volume 48,200
Day high $2.37 Avg. volume 52,492
50-day MA $2.13 Dividend yield N/A
200-day MA $2.39 Market Cap 112.32M

MediciNova, Inc. (MNOV) Company Bio


MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs for the United States market. The company was founded in 2000 and is based in La Jolla, California.


MNOV Latest News Stream


Event/Time News Detail
Loading, please wait...

MNOV Latest Social Stream


Loading social stream, please wait...

View Full MNOV Social Stream

Latest MNOV News From Around the Web

Below are the latest news stories about MEDICINOVA INC that investors may wish to consider to help them evaluate MNOV as an investment opportunity.

We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Yahoo | October 13, 2022

MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference

LA JOLLA, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will be conducting one-on-one virtual meetings with institutional investors as part of the Lytham Partners Fall 2022 Investor Conference. The event is taking place virtually on September 28 - 29, 2022. Yuichi Iwaki, MD, PhD, President and Chief Executive Of

Yahoo | September 15, 2022

MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma

LA JOLLA, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received an Issue Notification from the U.S. Patent and Trademark Office for a new patent which covers MN-166 (ibudilast) for the treatment of glioblastoma. This new patent is expected to expire no earlier than February 2039. The allowed claims cover a

Yahoo | September 14, 2022

MediciNova Poised To Receive Canadian Patents For Cholesterol Candidates

MediciNova Inc (NASDAQ: MNOV) received a Notice of Allowance Canadian patent covering MN-001 (tipelukast) and MN-002 (a significant metabolite of MN-001) for hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than July 2034. The allowed claims cover the use of MN-001 or MN-002 for reducing triglyceride blood level, total cholesterol blood level, and low-density lipoprotein (L

Yahoo | September 14, 2022

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada

LA JOLLA, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyp

Yahoo | September 13, 2022

Read More 'MNOV' Stories Here

MNOV Price Returns

1-mo 11.71%
3-mo 3.62%
6-mo N/A
1-year -28.88%
3-year -67.61%
5-year -67.56%
YTD -14.55%
2021 -49.05%
2020 -21.96%
2019 -17.50%
2018 26.28%
2017 7.30%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8053 seconds.